BRIANNA CRUMMEY: Open Payments
NPI 1316509771 · EASTMAN, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$691 in 35 payments from 15 companies in 2025. Trend: 2023 $474 · 2024 $749 · 2025 $691
Food & beverage: $691
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $120 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $92 |
| AstraZeneca Pharmaceuticals LP | 5 | $78 |
| Esperion Therapeutics, Inc. | 3 | $50 |
| Lilly USA, LLC | 2 | $40 |
| Lundbeck LLC | 2 | $38 |
| UCB, Inc. | 1 | $37 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Neurocrine BioSciences, Inc. | 1 | $21 |
Products named: REXULTI, Ozempic, Kerendia, NEXLETOL, BREZTRI, MOUNJARO, Briviact, AUSTEDO XR.
Industry payments across GA — which companies pay providers there.
